129 related articles for article (PubMed ID: 22196514)
21. Dihydropyridopyrazinones and dihydropteridinones as corticotropin-releasing factor-1 receptor antagonists: structure-activity relationships and computational modeling.
Dzierba CD; Tebben AJ; Wilde RG; Takvorian AG; Rafalski M; Kasireddy-Polam P; Klaczkiewicz JD; Pechulis AD; Davis AL; Sweet MP; Woo AM; Yang Z; Ebeltoft SM; Molski TF; Zhang G; Zaczek RC; Trainor GL; Combs AP; Gilligan PJ
J Med Chem; 2007 May; 50(9):2269-72. PubMed ID: 17402721
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis, and biological evaluation of 1,2,3,7-tetrahydro-6h-purin-6-one and 3,7-dihydro-1h-purine-2,6-dione derivatives as corticotropin-releasing factor(1) receptor antagonists.
Hartz RA; Nanda KK; Ingalls CL; Ahuja VT; Molski TF; Zhang G; Wong H; Peng Y; Kelley M; Lodge NJ; Zaczek R; Gilligan PJ; Trainor GL
J Med Chem; 2004 Sep; 47(19):4741-54. PubMed ID: 15341489
[TBL] [Abstract][Full Text] [Related]
23. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001.
Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Nakazato A; Kumagai T; Okubo T; Tomisawa K
J Pharmacol Exp Ther; 1999 May; 289(2):926-35. PubMed ID: 10215672
[TBL] [Abstract][Full Text] [Related]
24. Potent, orally active corticotropin-releasing factor receptor-1 antagonists containing a tricyclic pyrrolopyridine or pyrazolopyridine core.
Dyck B; Grigoriadis DE; Gross RS; Guo Z; Haddach M; Marinkovic D; McCarthy JR; Moorjani M; Regan CF; Saunders J; Schwaebe MK; Szabo T; Williams JP; Zhang X; Bozigian H; Chen TK
J Med Chem; 2005 Jun; 48(12):4100-10. PubMed ID: 15943483
[TBL] [Abstract][Full Text] [Related]
25. Design and synthesis of tricyclic corticotropin-releasing factor-1 antagonists.
Gross RS; Guo Z; Dyck B; Coon T; Huang CQ; Lowe RF; Marinkovic D; Moorjani M; Nelson J; Zamani-Kord S; Grigoriadis DE; Hoare SR; Crowe PD; Bu JH; Haddach M; McCarthy J; Saunders J; Sullivan R; Chen T; Williams JP
J Med Chem; 2005 Sep; 48(18):5780-93. PubMed ID: 16134945
[TBL] [Abstract][Full Text] [Related]
26. Chronic administration of the selective corticotropin-releasing factor 1 receptor antagonist CP-154,526: behavioral, endocrine and neurochemical effects in the rat.
Arborelius L; Skelton KH; Thrivikraman KV; Plotsky PM; Schulz DW; Owens MJ
J Pharmacol Exp Ther; 2000 Aug; 294(2):588-97. PubMed ID: 10900236
[TBL] [Abstract][Full Text] [Related]
27. Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists.
Hoare SR; Sullivan SK; Schwarz DA; Ling N; Vale WW; Crowe PD; Grigoriadis DE
Biochemistry; 2004 Apr; 43(13):3996-4011. PubMed ID: 15049707
[TBL] [Abstract][Full Text] [Related]
28. Receptor occupancy of nonpeptide corticotropin-releasing factor 1 antagonist DMP696: correlation with drug exposure and anxiolytic efficacy.
Li YW; Hill G; Wong H; Kelly N; Ward K; Pierdomenico M; Ren S; Gilligan P; Grossman S; Trainor G; Taub R; McElroy J; Zazcek R
J Pharmacol Exp Ther; 2003 Apr; 305(1):86-96. PubMed ID: 12649356
[TBL] [Abstract][Full Text] [Related]
29. Discovery of imidazo[1,2-b][1,2,4]triazines as GABA(A) alpha2/3 subtype selective agonists for the treatment of anxiety.
Russell MG; Carling RW; Street LJ; Hallett DJ; Goodacre S; Mezzogori E; Reader M; Cook SM; Bromidge FA; Newman R; Smith AJ; Wafford KA; Marshall GR; Reynolds DS; Dias R; Ferris P; Stanley J; Lincoln R; Tye SJ; Sheppard WF; Sohal B; Pike A; Dominguez M; Atack JR; Castro JL
J Med Chem; 2006 Feb; 49(4):1235-8. PubMed ID: 16480260
[TBL] [Abstract][Full Text] [Related]
30. In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.
Hartz RA; Ahuja VT; Rafalski M; Schmitz WD; Brenner AB; Denhart DJ; Ditta JL; Deskus JA; Yue EW; Arvanitis AG; Lelas S; Li YW; Molski TF; Wong H; Grace JE; Lentz KA; Li J; Lodge NJ; Zaczek R; Combs AP; Olson RE; Mattson RJ; Bronson JJ; Macor JE
J Med Chem; 2009 Jul; 52(14):4161-72. PubMed ID: 19552436
[TBL] [Abstract][Full Text] [Related]
31. Design and synthesis of tricyclic imidazo[4,5-b]pyridin-2-ones as corticotropin-releasing factor-1 antagonists.
Guo Z; Tellew JE; Gross RS; Dyck B; Grey J; Haddach M; Kiankarimi M; Lanier M; Li BF; Luo Z; McCarthy JR; Moorjani M; Saunders J; Sullivan R; Zhang X; Zamani-Kord S; Grigoriadis DE; Crowe PD; Chen TK; Williams JP
J Med Chem; 2005 Aug; 48(16):5104-7. PubMed ID: 16078829
[TBL] [Abstract][Full Text] [Related]
32. The behavioural and electrophysiological effects of CRF in rat frontal cortex.
Zieba B; Grzegorzewska M; Brański P; Domin H; Wierońska JM; Hess G; Smiałowska M
Neuropeptides; 2008; 42(5-6):513-23. PubMed ID: 18617263
[TBL] [Abstract][Full Text] [Related]
33. Optimization of 3-phenylpyrazolo[1,5-a]pyrimidines as potent corticotropin-releasing factor-1 antagonists with adequate lipophilicity and water solubility.
Chen C; Wilcoxen KM; Huang CQ; McCarthy JR; Chen T; Grigoriadis DE
Bioorg Med Chem Lett; 2004 Jul; 14(14):3669-73. PubMed ID: 15203140
[TBL] [Abstract][Full Text] [Related]
34. Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice.
Nielsen DM; Carey GJ; Gold LH
Eur J Pharmacol; 2004 Sep; 499(1-2):135-46. PubMed ID: 15363960
[TBL] [Abstract][Full Text] [Related]
35. Imidazo[4,5-b]pyridines as corticotropin releasing factor receptor ligands.
Arvanitis AG; Rescinito JT; Arnold CR; Wilde RG; Cain GA; Sun JH; Yan JS; Teleha CA; Fitzgerald LW; McElroy J; Zaczek R; Hartig PR; Grossman S; Arneric SP; Gilligan PJ; Olson RE; Robertson DW
Bioorg Med Chem Lett; 2003 Jan; 13(1):125-8. PubMed ID: 12467631
[TBL] [Abstract][Full Text] [Related]
36. Discovery of NBI-77860/GSK561679, a potent corticotropin-releasing factor (CRF1) receptor antagonist with improved pharmacokinetic properties.
Tellew JE; Lanier M; Moorjani M; Lin E; Luo Z; Slee DH; Zhang X; Hoare SR; Grigoriadis DE; St Denis Y; Di Fabio R; Di Modugno E; Saunders J; Williams JP
Bioorg Med Chem Lett; 2010 Dec; 20(24):7259-64. PubMed ID: 21074436
[TBL] [Abstract][Full Text] [Related]
37. Synthesis toward CRHR1 Antagonists through 2,7-Dimethylpyrazolo[1,5-α][1,3,5]triazin-4(3H)-one C-H Arylation.
Long J; Lee WS; Chough C; Bae IH; Kim BM
J Org Chem; 2015 May; 80(9):4716-21. PubMed ID: 25856509
[TBL] [Abstract][Full Text] [Related]
38. Corticotropin-releasing hormone receptor 1 antagonist blocks brain-gut activation induced by colonic distention in rats.
Saito K; Kasai T; Nagura Y; Ito H; Kanazawa M; Fukudo S
Gastroenterology; 2005 Nov; 129(5):1533-43. PubMed ID: 16285953
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis, and structure-activity relationships of a series of 2-Ar-8-methyl-5-alkylaminoquinolines as novel CRF₁ receptor antagonists.
Takeda K; Terauchi T; Hashizume M; Shin K; Ino M; Shibata H; Yonaga M
Bioorg Med Chem Lett; 2012 Sep; 22(17):5372-8. PubMed ID: 22871582
[TBL] [Abstract][Full Text] [Related]
40. Structure and Function of Small Non-Peptide CRF Antagonists and their Potential Clinical Use.
Fahmy H; Kuppast B; Ismail MT
Curr Mol Pharmacol; 2017; 10(4):270-281. PubMed ID: 27809751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
